微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 57.65% | -6.41% | -5.11% | 56/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 60.76% | -3.15% | -4.5% | 45/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 63.62% | 7.34% | 2.37% | 45/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 62.14% | -8.57% | 0.89% | 46/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 61.6% | -9.95% | -1.81% | 48/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 62.73% | -18.61% | 5.84% | 43/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 59.27% | -22.36% | -12.8% | 52/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 67.97% | -16.66% | -0.64% | 37/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 68.41% | -15.04% | -11.25% | 34/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 77.08% | -7.54% | 0.97% | 24/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 76.33% | -11.35% | -6.41% | 23/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 81.56% | -4.11% | 1.29% | 19/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 80.52% | -4.36% | -3.4% | 24/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 83.36% | -1.22% | -3.19% | 16/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 86.11% | 4.36% | 1.24% | 10/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 85.05% | 0.19% | 1.02% | 14/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 84.19% | -0.61% | -0.23% | 15/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 84.39% | 0.05% | 2.27% | 15/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 82.51% | -5.9% | -2.8% | 18/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 84.89% | -0.5% | 0.22% | 21/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 84.71% | -0.24% | 0.42% | 16/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 84.35% | -0.3% | -3.8% | 16/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 87.69% | 0.12% | 2.78% | 10/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 85.31% | 7.4% | 0.47% | 14/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 84.91% | 5.39% | 0.36% | 13/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 84.6% | 4.68% | -3.4% | 11/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 87.58% | 3.47% | 10.26% | 7/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 79.44% | 0.15% | -1.41% | 20/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 80.57% | -4.17% | -0.31% | 12/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 80.82% | -4.09% | -4.52% | 15/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 84.65% | -0.7% | 6.72% | 9/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 79.32% | 12.24% | -5.66% | 22/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 84.08% | 9.01% | -0.22% | 12/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 84.27% | 18.78% | -1.14% | 10/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 85.24% | 17.71% | 20.62% | 9/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 70.67% | 8.36% | -8.38% | 25/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 77.13% | 7.83% | 8.72% | 10/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 70.94% | -2.92% | -2.04% | 16/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 72.42% | -2.58% | 11.04% | 12/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 65.22% | -1.14% | -8.83% | 23/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 71.53% | 0.32% | -2.12% | 12/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 73.08% | 0.5% | -1.7% | 11/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 74.34% | -1.03% | 12.68% | 9/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |